FrancophonIA/ELRC3.0 huggingface dataset:
English: What measures are being taken to ensure the safe and effective use of Elocta?
Maltese: X'miżuri qegħdin jittieħdu biex jiġi żgurat l-użu sigur u effettiv ta' Elocta?
English: For the full list of side effects and restrictions of Elocta, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u r-restrizzjonijiet ta' Elocta, ara l-fuljett ta' tagħrif.
English: Elocta is a medicine used to treat and prevent bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of factor VIII).
Maltese: Elocta huwa mediċina li tintuża għall-kura u l-prevenzjoni ta' fsada f'pazjenti b'emofilja A (disturb ta' fsada li jintiret ikkawżat minn nuqqas ta' fattur VIII).
English: The European Medicines Agency therefore decided that Elocta's benefits are greater than its risks and it can be authorised for use in the EU.
Maltese: Għaldaqstant, lAġenzija Ewropea għall-Mediċini ddeċidiet li l-benefiċċji ta' Elocta huma akbar mir-riskji tiegħu u li jista' jiġi awtorizzat għall-użu fl-UE.
English: Studies show that Elocta is effective at preventing and treating bleeding episodes in patients with haemophilia A and its safety is in line with what is expected for medicines of its kind.
Maltese: L-istudji juru li Elocta huwa effikaċi fil-prevenzjoni u fil-kura ta' episodji ta' fsada f'pazjenti b'emofilja A u s-sigurtà tiegħu hija konformi ma' dak li hu mistenni għal mediċini ta' dan it-tip.
English: Side effects reported with Elocta are carefully evaluated and any necessary action taken to protect patients.
Maltese: L-effetti sekondarji rrappurtati b'Elocta huma evalwati bir-reqqa u kull azzjoni meħtieġa hi meħuda biex tipproteġi lill-pazjenti.
English: How does Elocta work?
Maltese: Kif jintuża Elocta?
English: o Class I or Class III antiarrhythmics.
Maltese: ○ antiarritmiċi ta' Klassi I jew ta' Klassi
English: • Contraindication: o CYP3A inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, telithromycin, clarithromycin, nefazodone and ritonavir.
Maltese: ○ inibituri ta' CYP3A li jinkludu ketoconazole, itraconazole, voriconazole, posaconazole, telithromycin, clarithromycin, nefazodone u ritonavir.
English: • Use with caution: in association with digoxin, beta blockers, calcium antagonists, statins and vitamin K antagonists.
Maltese: • Uża b'kawtela: flimkien ma' digoxin, beta-blokkanti, antagonisti tal-kalċju u statins.
English: • Not recommended/to be avoided: o grapefruit juice, o potent CYP3A4 inducers including rifampicin, phenobarbital, carbamazepine, phenytoin, St John's Wort o dabigatran.
Maltese: ○ il-meraq tal-grejpfrut, ○ mediċini li b'mod qawwi jistimlaw l-enzima CYP3A4 li jinkludu rifampicin, phenobarbital, carbamazepine, phenytoin, St John's Wort.
English: • That patients should be counselled that: they should consult a physician if they develop or experience worsening signs or symptoms of heart failure; they should immediately report to a physician any symptoms of potential liver injury; MULTAQ interacts with a number of medicines; if they consult other doctors they should inform them that they are taking MULTAQ; they should not take St John's Wort with MULTAQ; they should avoid grapefruit juice.
Maltese: • Li l-pazjenti għandhom jiġu mgħarrfa li : għandhom jaraw tabib jekk jiżviluppaw jew jkollhom sinjali jew sintomi ta' insuffiċjenza talqalb li jmorru għall-agħar. għandhom jirrapportaw ma' tabib kull sintomu li jista' jindika ħsara fil-fwied. numru ta' mediċini jistgħu jbidlu l-effett farmaċewtiku ta' MULTAQ. jekk imorru għand tobba oħra għandhom jgħidulhom li qegħdin jieħdu MULTAQ. m'għandhomx jieħdu St John's Wort ma' MULTAQ. għandhom jevitaw il-meraq tal-grejpfrut.
English: • That the use of MULTAQ is not recommended in patients with recent (1-3 months) stable NYHA class III heart failure or with LVEF <35%.
Maltese: Li l-użu ta' MULTAQ mhux rakkomandat f'pazjenti li reċentement (1-3 xhur) kellhom insuffiċjenza ta' qalb li kienet stabbli u tat-tip NYHA ta' klassi III jew LVEF <35 %.
English: o potential torsades de pointes inducers including phenothiazines, cisapride, bepridil, tricyclic antidepressants, terfenadine and certain oral macrolides.
Maltese: ○ mediċini li għandhom il-potenzjal li jikkawża torsades de pointe li jinkludu phenothiazines, cisapride, bepridil, antidipressivi triċikliċi, terfenadine u xi makrolidi orali.
English: The MULTAQ Information Card should contain the following key safety messages:
Maltese: Il-Fuljett ta' Informazzjoni dwar MULTAQ għandu jkollu dawn il-messaggi importanti dwar issigurtà::
English: • That liver function tests should be performed prior and during treatment.
Maltese: • Li testijiet dwar il-funzjoni tal-fwied għandhom isiru qabel u waqt il-kura.
English: • That MULTAQ must not be used in patients with unstable haemodynamic conditions including patients with symptoms of heart failure at rest or with minimal exertion (corresponding to NYHA class IV and unstable class III patients).
Maltese: • Li MULTAQ m'għandux jintuża f'pazjenti b'kundizzjonijiet emodinamiċi li mhumiex stabbli inklużi pazjenti b'sintomi ta' insuffiċjenza tal-qalb waqt il-mistrieħ jew waqt eżerċizzju minimu ( li skont il-klassifika NYHA jikkorrispondu għal pazjenti ta' klassi IV u ta' klassi
English: The Marketing Authorisation Holder shall ensure that Health care professionals who intend to prescribe or dispense MULTAQ are provided with an SPCand the MULTAQ Information Card.
Maltese: Lill-professjonisti fil-kura tas-saħħa li jkollhom l-intenzjoni jiktbu riċetta jew jagħtu MULTAQ, idDetentur tal-Awtorizzazzjoni għat-Tqegħid fis-Suq irid jassigura li se jipprovdi SPC u l-Fuljett ta' Informazzjoni dwar MULTAQ.
English: The content and format of the MULTAQ Information Card, together with the communication and distribution plan should be agreed with the National Competent Authority in each Member State prior to distribution.
Maltese: Qabel ma ssir id-distribuzzjoni, għandu jkun hemm ftehim malAwtorità Kompetenti Nazzjonali ta' kull Stat Membru fuq il-kontenut u d-dehra tal-Fuljett ta' Informazzjoni dwar MULTAQ, kif ukoll dwar il-pjan ta' komunikazzjoni u distribuzzjoni.
English: The MULTAQ Information Card should contain a list of drugs which interact with MULTAQ classified according to the seriousness of the interaction (eg contraindication, not recommended, use with caution).
Maltese: 2.Il-Fuljett ta' Informazzjoni dwar MULTAQ irid ikollu fih lista ta' mediċini li għandhom interazzjoni ma' MULTAQ ikklassifikati skont is-serjetà ta' din l-interazzjoni (eż. kontra-indikazzjoni, mhux rakkomandat, uża b'kawtela).
English: However, the following side effects are seen in between 1 and 10 patients in 1,000: upper respiratory tract infection (colds) including inflammation of the throat and sinuses, urinary tract infection (infection of the structures that carry urine) including bladder infection, anaemia (low red blood cell counts), hyperkalaemia (high blood potassium levels), depression, insomnia (difficulty sleeping), syncope (fainting), vertigo (a spinning sensation), bradycardia (slow heart rate), hypotension (low blood pressure), dyspnoea (difficulty breathing), cough, abdominal pain (stomach ache), diarrhoea, dyspepsia (heartburn), flatulence (gas), vomiting, hyperhidrosis (excessive sweating), pruritus (itching), rash, myalgia (muscle pain), back pain, muscle spasms, renal impairment (reduced kidney function) including sudden kidney failure, chest pain, asthenia (weakness) and increased blood levels of creatinine (a marker of muscle breakdown).
Maltese: Madankollu, l-effetti sekondarji li dehru f'bejn 1 u 10 pazjenti minn kull 1,000: infezzjonijiet fil-parti tan-nifs (irjiħat) fosthom infjammazzjoni talgriżmejn u s-sinus, infezzjoni fl-apparat urinarju (infezzjoni fl-istrutturi li jġorru l-awrina) fosthom linfezzjoni fil-bużżieqa, anemija (tnaqqis fil-għadd ta' ċelloli ħomor tad-demm), iperkalemija (livelli għoja ta' potassju fid-demm), dipressjoni, insonnja (diffikultà fl-irqad), sinkope (tħossok ħażin), mejt (vertiġini, sens ta' tidwir), bradikardija (taħbit tal-qalb mhux mgħaġġel), ipotensjoni (pressjoni baxxa), dispnea (diffikultà fin-nifs), sogħla, uġigħ addominali (uġigħ fl-istonku), dijarrea, dispepsija (ħruq ta' stonku), flatulenza (gass), remettar, iperidrożi (għaraq eċċessiv), prurite (ħakk), raxx, mijalġija (uġigħ fil-muskoli), uġigħ fid-dahar, spażmi tal-muskolu, indeboliment renali (problemi fil-kliewi) inkluża linsuffiċjenza renali f'salt (insuffiċjenza tal-kliewi), uġigħ fis-sider, astenja (djgħufija) u livelli ogħla ta' kreatina fid-demm (marker tad-diżintegrazzjoni tal-muskoli).
English: Kinzalmono is a medicine that contains the active substance telmisartan.
Maltese: Kinzalmono huwa mediċina li fiha s-sustanza attiva telmisartan.
English: This summary was last updated in 08-2015.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'08-2015.
English: Various doses of Kinzalmono were compared with placebo (a dummy treatment) and with other medicines for hypertension (atenolol, lisinopril, enalapril and amlodipine).
Maltese: Diversi dożi differenti ta' Kinzalmono tqabblu ma' plaċebo (kura finta) jew ma' mediċini oħra għall-ipertensjoni (atenolol, lisinopril, enalapril u amlodipina).
English: This is a summary of the European public assessment report (EPAR) for Kinzalmono.
Maltese: Dan id-dokument huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Kinzalmono.
English: For the prevention of cardiovascular problems, 80 mg Kinzalmono once a day has been studied in one main study involving almost 26,000 patients aged 55 years or over who had heart or artery disease, had had a stroke, or had diabetes and were at high risk of cardiovascular problems.
Maltese: Għall-prevenzjoni ta' problemi kardjovaskulari, id-doża ta' 80 mg ta' Kinzalmono darba kuljum ġiet studjata fi studju li involva kważi 26,000 pazjent minn 55 sena 'l fuq li kellhom mard fil-qalb jew flarterji, puplesija, jew kellhom id-diabete u kienu f'riskju għoli ta' problemi kardjovaskulari.
English: What is Kinzalmono?
Maltese: Kif jintuża Kinzalmono?
English: For the treatment of essential hypertension, the usual recommended dose of Kinzalmono is 40 mg once a day, but some patients may benefit from using 20 mg once a day.
Maltese: Għall-kura tal-ipertensjoni essenzjali, normalment id-doża rakkomandata ta' Kinzalmono hija 40 mg darba kuljum, iżda xi pazjenti jistgħu jibbenefikaw mill-użu ta' doża ta' 20 mg darba kuljum.
English: Why has Kinzalmono been approved?
Maltese: Għaliex ġie approvat Kinzalmono?
English: For the treatment of essential hypertension, Kinzalmono has been studied in 2,647 patients who took Kinzalmono either alone or in combination with hydrochlorothiazide.
Maltese: Għall-kura tal-ipertensjoni essenzjali, Kinzalmono ġie studjat f'2,647 pazjent li ħadu Kinzalmono jew waħdu jew inkella flimkien mal-idroklorotijażide.
English: Kinzalmono was compared with ramipril (another medicine to prevent cardiovascular problems), and with the combination of both medicines.
Maltese: Kinzalmono tqabbel ma' ramipril (mediċina oħra li tipprevjeni problemi kardjovaskulari), kif ukoll mat-taħlita tażżewġ mediċini.
English: Side effects with Kinzalmono are not common.
Maltese: L-effetti sekondarji b'Kinzalmono mhumiex komuni.
English: The full EPAR for Kinzalmono can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports Għal aktar informazzjoni rigward il-kura b'Kinzalmono, aqra l-fuljett ta' tagħrif (parti wkoll mill-EPAR) jew ikkuntattja lit-tabib jew lill-ispiżjar tiegħek.
English: What is the risk associated with Kinzalmono?
Maltese: X'inhu r-riskju assoċjat ma' Kinzalmono?
English: In the prevention of cardiovascular problems, Kinzalmono had a similar effect to ramipril, with around 17% of patients dying, being admitted to hospital because of cardiovascular problems, or having a heart attack or stroke.
Maltese: Għall-prevenzjoni ta' problemi kardjovaskulari, Kinzalmono kellu effett simili għal ramipril, b'madwar 17% tal-pazjenti li mietu, iddaħlu l-isptar minħabba problemi kardjovaskulari, jew kellhom attakk talqalb jew puplesija.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Kinzalmono on 16 December 1998.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq madwar l-Unjoni Ewropea, għal Kinzalmono fis-16 ta' Diċembru 1998.
English: The active substance in Kinzalmono, telmisartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Maltese: Kinzalmono jintuża fil-kura tal-ipertensjoni essenzjali (pressjoni tad-demm għolja) fl-adulti. ‘Essenzjali' tfisser li l-ipertensjoni ma jkollhiex kawża evidenti.
English: Patients with mild or moderately reduced liver function should not receive doses higher than 40 mg a day.
Maltese: Il-pazjenti li jbatu minn indeboliment ħafif jew moderat fil-fwied ma għandhomx jingħataw dożi ogħla minn 40 mg kuljum.
English: It also allows the heart to pump blood more easily, which can help to reduce the risk of future cardiovascular problems.
Maltese: Jippermetti wkoll lill-qalb sabiex tippompja d-demm aktar faċilment, li jista' jgħin sabiex jitnaqqas irriskju ta' problemi kardjovaskulari futuri.
English: Hypotension may be more common in patients receiving Kinzalmono to prevent cardiovascular problems.
Maltese: L-ipotensjoni tista' tkun iżjed komuni f'pazjenti li jkunu qed jingħataw Kinzalmono għall-prevenzjoni ta' problemi kardjovaskulari.
English: If the target blood pressure is not reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.
Maltese: Jekk ilpressjoni tad-demm fil-mira ma tintlaħaqx, id-doża tista' tiżdied għal 80 mg, jew tista' tiżdied mediċina oħra għall-ipertensjoni, bħall-idroklorotijażide.
English: How has Kinzalmono been studied?
Maltese: Kif ġie studjat Kinzalmono?
English: Kinzalmono must not be used in people who have severe liver problems or bile problems.
Maltese: Kinzalmono ma għandux jintuża f'persuni li jkollhom problemi gravi fil-fwied jew problemi biljari.
English: NovoNorm is a medicine that contains the active substance repaglinide.
Maltese: NovoNorm huwa mediċina li fiha s-sustanza attiva repaglinide.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NOVONORM EPAR summary for the public
Maltese: RAPPORT TA' VALUTAZZJONI PUBBLIKA EWROPEW (EPAR) NOVONORM Sommarju tal-EPAR għall-pubbliku
English: A total of 2,156 patients received NovoNorm in all trials combined.
Maltese: Total ta' 2 156 pazjent irċevew NovoNorm fil-provi kollha kkombinati.
English: The marketing authorisation was renewed on 17 August 2003 and on 17 August 2008.
Maltese: L-awtorizzazzjoni għat-tqegħid fissuq ġiet imġedda fis-17 ta' Awwissu 2003 u fis-17 ta' Awwissu 2008.
English: It is available as round tablets (white: 0.5 mg; yellow: 1 mg; peach: 2 mg).
Maltese: Huwa disponibbli f'pilloli tondi (bojod: 0.5 mg; sofor: 1 mg; lewn il-ħawħ:
English: The most common side effects with NovoNorm (seen in between 1 and 10 patients in 100) are hypoglycaemia (low blood glucose levels), abdominal (tummy) pain and diarrhoea.
Maltese: L-effetti sekondarji l-iktar komuni b'NovoNorm (li dehru f'bejn 1 u 10 pazjenti minn kull 100) huma ipogliċemija (livelli baxxi ta' glukożju fid-demm), uġigħ addominali (taż-żaqq) u dijarrea.
English: If patients are transferred from another anti-diabetes medicine, the recommended starting dose is 1 mg.
Maltese: Jekk pazjenti qalbu minn mediċina kontra d-dijabete oħra, id-doża inizjali rakkomandata hija 1 mg.
English: What is the risk associated with NovoNorm?
Maltese: X'inhu r-riskju assoċjat ma' NovoNorm?
English: The European Commission granted a marketing authorisation valid throughout the European Union for NovoNorm to Novo Nordisk A/S on 17 August 1998.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida madwar l-Unjoni Ewropea, għal NovoNorm lil Novo Nordisk A/S fis-17 ta' Awwissu 1998.
English: Why has NovoNorm been approved?
Maltese: Għaliex ġie approvat NovoNorm?
English: NovoNorm has been studied in 45 ‘clinical pharmacology' studies (looking at how the medicine works in the body) and 16 clinical trials (looking at its effects in treating type 2 diabetes patients).
Maltese: NovoNorm ġie studjat f'45 studju ‘kliniku farmakoloġiku' (li eżaminaw kif il-mediċina taħdem filġisem) u f'16-il prova klinika (li eżminaw l-effetti tiegħu fit-trattament ta' pazjenti b'dijabete tat-tip 2).
English: This summary was last updated in 07-2008.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar fi: 07-2008.
English: What is NovoNorm?
Maltese: X'inhu NovoNorm?
English: The raised insulin levels returned to normal after the meal.
Maltese: Il-livelli ta' insulina li kienu telgħu, reġgħu għan-normal wara l-ikla.
English: NovoNorm is taken before meals, normally up to 15 minutes before each main meal.
Maltese: NovoNorm jingħata qabel l-ikel, is-soltu sa 15-il minuta qabel kull ikla prinċipali.
English: How has NovoNorm been studied?
Maltese: Kif ġiet studjata NovoNorm?
English: In the study where NovoNorm was added to metformin, the effects of the two medicines were at least additive (equivalent to the effects of the two medicines added together).
Maltese: Fl-istudju fejn NovoNorm ġie miżjud mal-metformina, l-effetti taż-żewġ mediċini kienu talanqas addittivi (ekwivalenti għall-effetti taż-żewġ mediċini mħalltin flimkien).
English: The studies measured the level of a substance in the blood called glycosylated haemoglobin (HbA1c) which gives an indication of how well the blood glucose is controlled.
Maltese: Listudji kejlu l-livell fid-demm ta' sustanza magħrufa bħala emoglobina glikosilata (HbA1c).
English: For the full list of all side effects reported with NovoNorm, see the Package Leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha rrappurtati b'NovoNorm, ara l-Fuljett ta' Tagħrif.
English: NovoNorm helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes.
Maltese: NovoNorm jgħin lill-frixa tipproduċi iktar insulina f'ħin l-ikel u jintuża biex jikkontrolla dijabete tat-tip 2.
English: NovoNorm may also be used with metformin (another anti-diabetes medicine) in type 2 diabetes patients whose blood glucose levels are not satisfactorily controlled on metformin alone.
Maltese: NovoNorm jista' jintuża wkoll mal-metformina (mediċina oħra kontra d-dijabete) f'pazjenti b'dijabete tat-tip 2 li jkollhom livelli ta' glukożju fid-demm li ma jkunux ikkontrollati biżżejjed bl-użu tal-metformina waħedha.
English: NovoNorm produced a good insulin response to a meal within 30 minutes of being dosed in type 2 diabetes patients, leading to a blood glucose-lowering effect throughout the meal.
Maltese: NovoNorm ipproduċa rispons tajjeb ta' insulina għal ikla fi żmien 30 minuta minn meta ngħata lil pazjenti b'dijabete tat-tip 2, li wassal għal tnaqqis tal-glukożju fid-demm matul l-ikla.
English: It should also not be used in patients with diabetic ketoacidosis (high levels of ketones [acids] in the blood), in patients with severe liver problems or in patients also taking gemfibrozil (a medicine used to reduce blood fat levels).
Maltese: M'għandux jintuża wkoll f'pazjenti b'ketoaċidożi dijabetika (livelli għoljin ta' ketoni [aċidi] fid-demm), f'pazjenti bi problemi severi fil-fwied jew f'pazjenti li jkunu qegħdin jieħdu wkoll gemfibrozil (mediċina użata biex tnaqqas il-livelli ta' xaħam fid-demm).
English: NovoNorm is used in patients who have type 2 diabetes (non-insulin-dependent diabetes).
Maltese: Novonorm jintuża fit-trattament ta' pazjenti adulti li jbatu mid-dijabete tat-tip 2 (dijabete mhux dipendenti mill-insulina).
English: It is used together with diet and exercise to lower blood glucose (sugar) levels in patients whose hyperglycaemia (high blood glucose levels) cannot be controlled by diet, weight reduction and exercise.
Maltese: Jintuża flimkien ma' dieta u eżerċizzju biex ibaxxi l-livell ta' glukożju (zokkor) fid-demm f'pazjenti li jkollhom ipergliċemija (livelli għoljin ta' glukożju fid-demm) li ma tkunx tista' tiġi kkontrollata minn dieta, tnaqqis fil-piż u eżerċizzju.
English: The main studies compared NovoNorm with other medicines used in type 2 diabetes (glibenclamide, glipizide or gliclazide).
Maltese: L-istudji ewlenin qabblu NovoNorm ma' mediċini oħra użati f'dijabete tat-tip 2 (glibenclamide, glipizide jew gliclazide).
English: The Committee for Medicinal Products for Human Use (CHMP) decided that NovoNorm's benefits are greater than its risks for the treatment of type 2 diabetes.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) iddeċieda li NovoNorm għandu iktar benefiċċji milli riskji fit-trattament tad-dijabete tat-tip 2.
English: NovoNorm is not recommended for patients below 18 years of age because of a lack of information on safety and effectiveness in this age group.
Maltese: NovoNorm mhux rakkomandat sabiex jintuża f'pazjenti ta' inqas minn 18-il sena minħabba nuqqas ta' tagħrif dwar is-sigurtà u l-effikaċja f'dan il-grupp.
English: Luxembourg Pierre Fabre Médicaments
Maltese: Lussemburgu Pierre Fabre Médicaments
English: Farmaceutyczna Spółdzielnia Pracy FILOFARM ul.
Maltese: Farmaceutyczna Spółdzielnia Pracy FILOFARM
English: TAMIK, capsule soft capsule
Maltese: TAMIK, capsule kapsula ratba
English: Alfa Wasserman Pharma SAS 67 rue Anatole France, 92300 Levallois Perret France
Maltese: Wasserman Pharma SAS 67 rue Anatole France, 92300 Levallois
English: Edifícios AzevedosEstrada Nacional 117-2, Alfragide
Maltese: Nacional 117-2, Alfragide
English: SEGLOR 5 mg, gélule 5 mg hard capsule
Maltese: SEGLOR 5 mg, gélule 5 mg kapsula iebsa
English: SEGLOR LYOC 5 mg, lyophilisat oral oral lyophilisate
Maltese: SEGLOR LYOC 5 mg, lyophilisat oral lajofiliżejt orali
English: 2.5 mg tablet
Maltese: 2.5 mg pillola
English: Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml oral drops, solution oral use ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
Maltese: - Tropfen 2 mg/ml, 10 mg/ml qtar orali, soluzzjoni ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
English: Dihydergot 2,5 mgTabletten
Maltese: Dihydergot 2,5 mgPillolaten
English: Ditamin 2,5 mg tablete 2,5 mg
Maltese: Ditamin 2,5 mg pillolae 2,5 mg
English: DHE "ratiopharm" 2,5 mg - Kapseln prolonged-release capsule, hard ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
Maltese: DHE "ratiopharm" 2,5 mg - Kapseln ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
English: IKARAN L.P. 5 mg, comprimé à libération prolongée prolonged-release tablet
Maltese: IKARAN L.P. 5 mg, comprimé à libération prolongée pillola li terħi lmediċina b'mod modifikat
English: DIHYDROERGOTAMINE AMDIPHARM 3 mg, comprimé
Maltese: AMDIPHARM 3 mg, comprimé
English: CT Arzneimittel GmbH Lengeder Str. 42 a D-13407 Berlin Germany
Maltese: 42 a D-13407 Berlin Germany
English: DHE "ratiopharm" 5 mg - Kapseln prolonged-release capsule, hard
Maltese: DHE "ratiopharm" 5 mg - Kapseln
English: Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna Austria
Maltese: Boehringer-Gasse 5-11, A-1121 Vienna Austria
English: 0.20 g /100 ml oral drops, solution oral use
Maltese: 0.20 g /100 ml qtar orali, soluzzjoni
English: 2 mg/ml oral solution
Maltese: 2 mg/ml soluzzjoni orali
English: Ergovasan 5 mg retard - Kapseln prolonged-release capsule, hard
Maltese: Ergovasan 5 mg retard - Kapseln
English: Ergovasan 2,5 mg retard - Kapseln prolonged-release capsule, hard
Maltese: Ergovasan 2,5 mg retard - Kapseln
English: AMDIPHARM Temple Chambers 3, Burlington Road DUBLIN 4
Maltese: Temple Chambers 3, Burlington Road DUBLIN 4
English: 0.20 g /100 ml oral solution
Maltese: 0.20 g /100 ml
English: 2 mg/ 1 ml solution
Maltese: 2 mg/ 1 ml
English: Amdipharm Ltd. 3, Burlington Road, Temple Chambers, Dublin 4
Maltese: 3, Burlington Road, Temple Chambers, Dublin 4
English: 2 mg/ml oral drops, solution oral use
Maltese: 2 mg/ml qtar orali, soluzzjoni
English: Ergotam-CT 5,0mg Retardkapseln
Maltese: Ergotam-CT 5,0mg Retardkapseln kapsula li terħi lmediċina b'mod modifikat